Q2 2025 Jubilant Ingrevia Ltd Earnings Call Transcript
Key Points
- Jubilant Ingrevia Ltd (BOM:543271) reported a healthy quarter-on-quarter and year-on-year growth, driven by enhanced performance in specialty chemicals and nutrition, health, and solutions business.
- The company signed a significant five-year contract with a multinational agro-innovator, expected to boost revenue share from its agrichemical CDMO business.
- Jubilant Ingrevia Ltd (BOM:543271) was recognized by the World Economic Forum as a global manufacturing lighthouse, highlighting its advancements in digital transformation and sustainability.
- The company maintained strong market positions, being the global leader in Pyridine & Picoline and among the top two players in food-grade Niacinamide.
- Exports grew by 30% year-over-year, with increased interest from global clients due to the China plus one strategy, reducing reliance on the domestic market.
- The Acetyl business faced pressure due to low demand in the Paracetamol segment, impacting overall performance.
- Despite year-on-year growth, the Chemical Intermediates Business saw a decline in performance due to lower prices.
- Pricing pressure persisted in the Choline segment due to high imports, affecting margins.
- The company anticipates a gradual recovery in the agrochemical sector, indicating ongoing challenges in demand stabilization.
- Significant capital expenditure is required to prepare facilities for new contracts, which may impact short-term financials.
Ladies and gentlemen, good day and welcome to Jubilant Ingrevia's Q2 FY25 earnings conference call.
As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes.
(operator Instructions)
I now hand the conference over to Mr. Pavleen Taneja, head of Investor Relations at Jubilant Ingrevia Limited.
Thank you, and over to you Mr. Taneja.
Thank you Dolwin. Good evening everyone. Thank you for joining our quarter two of financial year 2025 earnings conference call of Jubilant Ingrevia Limited.
I would like to remind you that some of the statements made on the call today could be forward-looking in nature.
And a detailed disclaimer in this regard has been included in the press release and results presentation that has been shared on our website. On the call today, we have Mr Shyam Bhartia, Chairman; Mr Deepak Jain, CEO and managing director
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
